Once-weekly epoetin-beta improves hemoglobin levels in cancer patients with chemotherapy-induced anemia: A randomized, double-blind, dose-finding study.
OBJECTIVE
To determine a recommended dose of once-weekly epoetin-beta administration for anemic cancer patients receiving myelosuppressive chemotherapy, we conducted a multicenter, randomized, double-blind trial.


METHODS
A total of 86 patients with malignant lymphoma or lung cancer who received chemotherapy containing platinum, taxanes or anthracyclines were enrolled in the study. Patients were randomly assigned into groups that received three dose levels of epoetin-beta (9000, 18,000 or 36,000 IU) administered subcutaneously once a week for 12 weeks. The primary endpoint was change in hemoglobin, while the secondary endpoints were quality of life (QOL) assessed by Functional Assessment of Cancer Therapy-Anemia (FACT-An) questionnaire and transfusion requirements.


RESULTS
Among the 69 patients (per protocol set population) assessable for efficacy, hemoglobin level change in the 36,000 IU group was significantly greater than that in the 9000 IU group (1.75 +/- 2.15 versus 0.04 +/- 1.98 g/dl; P = 0.009), and a significant dose-response relationship was observed for the change in hemoglobin level (P = 0.003). Although changes in FACT-An Total Fatigue subscale (Fatigue subscale) scores were similar for the three dosage groups, there was a statistically significant correlation (r = 0.435, P < 0.001) between the change in hemoglobin levels and the change in Fatigue subscale scores. The proportion of transfused patients was significantly smaller in the 36 000 IU group compared with that in the 9000 IU group (P = 0.022, not adjusted for pre-study transfusions). The incidence of adverse events was similar in the three dosage groups.


CONCLUSIONS
Once-weekly epoetin-beta 36,000 IU for 12 weeks was well tolerated and significantly increased hemoglobin levels in anemic cancer patients receiving chemotherapy.
Morishima
Yasuo
Y
Department of Hematology and Cell Therapy, Aichi Cancer Center Hospital, Nagoya, Japan. ymorisim@aichi-cc.jp
Ogura
Michinori
M
Yoneda
Shuichi
S
Sakai
Hiroshi
H
Tobinai
Kensei
K
Nishiwaki
Yutaka
Y
Minami
Hironobu
H
Hotta
Tomomitsu
T
Ezaki
Kohji
K
Ohe
Yuichiro
Y
Yokoyama
Akira
A
Tsuboi
Masahiro
M
Mori
Kiyoshi
K
Watanabe
Koshiro
K
Ohashi
Yasuo
Y
Hirashima
Kunitake
K
Saijo
Nagahiro
N
D000328:Adult; D000368:Aged; D000740:Anemia / Q000139:chemically induced / Q000188:drug therapy* / Q000628:therapy; D018943:Anthracyclines / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects*; D001952:Bridged-Ring Compounds / Q000008:administration & dosage; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D017707:Erythrocyte Transfusion; D004921:Erythropoietin / Q000008:administration & dosage* / Q000009:adverse effects; D005260:Female; D006454:Hemoglobins / Q000032:analysis*; D006801:Humans; D007970:Leukopenia / Q000139:chemically induced; D008175:Lung Neoplasms / Q000097:blood / Q000188:drug therapy*; D008223:Lymphoma / Q000097:blood / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D017671:Platinum Compounds / Q000008:administration & dosage; D011788:Quality of Life; D011994:Recombinant Proteins; D043823:Taxoids / Q000008:administration & dosage
D018943:Anthracyclines; D001952:Bridged-Ring Compounds; D006454:Hemoglobins; D017671:Platinum Compounds; D011994:Recombinant Proteins; D043823:Taxoids; C103998:epoetin beta; D004921:Erythropoietin; C080625:taxane